CE for Pharmacists: Updates on Glucagon-Like Peptide-Based Medications: Current, New, and Pipeline Agents
by Elizabeth A. Buckley, PharmD, CDCES, Francesca Napolitano Johnson, PharmD, MEd, Denise Walbrandt Pigarelli, PharmD, BC-ADM
Learning Objectives
Keywords: Semaglutide, Glucagon, Dulaglutide, Exenatide, Incretins, Liraglutide, Glycated Hemoglobin, Insulin, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide 1, Blood Glucose, Diabetes Mellitus, Type 2, Glucose, Incidence, Financial Stress, Cardiovascular Diseases, Hypoglycemia, Hyperglycemia, Fasting, Kidney, Liver, Body Weight, Stomach, Drug-Related Side Effects and Adverse Reactions, Risk Factors
Download PDF
2023 May/June Table of Contents
Learning Objectives
- Compare and contrast the currently available glucagon-like peptide-1 receptor agonists (GLP1-RA)
- Describe the mechanism and advantages of tirzepatide
- Identify trends in pipeline GLP1-RA-based-medications
Keywords: Semaglutide, Glucagon, Dulaglutide, Exenatide, Incretins, Liraglutide, Glycated Hemoglobin, Insulin, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide 1, Blood Glucose, Diabetes Mellitus, Type 2, Glucose, Incidence, Financial Stress, Cardiovascular Diseases, Hypoglycemia, Hyperglycemia, Fasting, Kidney, Liver, Body Weight, Stomach, Drug-Related Side Effects and Adverse Reactions, Risk Factors
Download PDF
2023 May/June Table of Contents